Cantargia (Nasdaq Stockholm: CANTA) has announced the appointment of Wolfram Dempke, MD, PhD, MBA as chief medical officer (CMO), effective immediately. Dr. Morten Lind Jensen, who has served as CMO since March 2025, will leave Cantargia to pursue other opportunities.
Dr. Dempke is an internationally recognized expert in hematology and oncology with more than 30 years of experience in academia, clinical research, and the pharmaceutical industry.
Hilde Steineger, CEO of Cantargia, commented, “We are delighted to welcome Dr. Dempke to Cantargia. He brings experience and expertise in oncology drug research and development that are critical for our continued journey, not the least his knowledge and track record in the pancreatic cancer field. I would also like to take the opportunity to thank Dr. Morten Lind Jensen for his dedicated contribution and wish him continued success in his future endeavors.”
